Press releases
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
More ▼
Key statistics
As of last trade Chromadex Corp (OCD1:FRA) traded at 3.50, -13.79% below its 52-week high of 4.06, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.50 |
---|---|
High | 3.50 |
Low | 3.50 |
Bid | 3.46 |
Offer | 3.52 |
Previous close | 3.48 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.52m |
Free float | 48.49m |
P/E (TTM) | -- |
Market cap | 286.99m USD |
EPS (TTM) | -0.0659 USD |
Data delayed at least 15 minutes, as of May 07 2024 07:17 BST.
More ▼